Abstracts tagged "Behçet’s Syndrome"

Abstract Number: 1562 • ACR Convergence 2023
Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population
Sundus Mian¹, Talia Meisel², Hussain Md¹, Xianhong Xie³, Tamara Tanner¹, Anand Kumthekar⁴ and Bibi Ayesha⁴, ¹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
Background/Purpose: Behcet's disease (BD) is a vasculitis with both thrombotic and bleeding complications which can make management challenging. Thrombosis is due to direct vascular inflammation,…
Abstract Number: 0258 • ACR Convergence 2023
Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation
Patricia Aires¹, Daniela Pioto¹, Maria Teresa TErreri² and Sandro Perazzio³, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de Sao Paulo (Unifesp); Universidade de São Paulo (USP); Fleury Laboratories, São Paulo, Brazil
Background/Purpose: A20, encoded by TNFAIP3, plays a critical role in NF-κB pathway regulation. A20 haploinsufficiency is a monogenic disorder form of Behçet's disease with a…
Abstract Number: 1563 • ACR Convergence 2023
Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease
Miriam Retuerto-Guerrero¹, Elvira Díez Álvarez¹, Javier Narvaez², Rosa Fornons Servent³, Carlos Moreno Vilchez³, Jenaro Graña Gil⁴, Uxía Couto Lareo⁵, Carmen San José-Méndez⁴ and Clara Moriano Morales¹, ¹Rheumatology, Hospital Universitario de León, León, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Dermatology, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Rheumatology, Hospital A Coruña, A Coruña, Spain, ⁵Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Behçet's disease (BD) is characterized by great clinical heterogeneity. The therapeutic strategy for BD could be tailored to the specific needs of the patient,…
Abstract Number: 0692 • ACR Convergence 2023
Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Johannes Nowatzky¹, Ziyan Lin², Yesim Ozguler³, Alireza Khodadadi-Jamayran², Didar Ucar⁴, Aristotelis Tsirigos⁵, Gulen Hatemi⁶ and Olivier Manches⁷, ¹NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, ²NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁵NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France
Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…
Abstract Number: 1564 • ACR Convergence 2023
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease
fatma Alibaz-Öner¹, Rabia Ergelen², Seda Kutluğ Ağaçkıran³, Fatma Temiz⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Marmara University, School of Medicine, Department of Radiology, Istanbul, Turkey, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁶Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on multi-systemic clinical manifestations after ruling out other potential causes. There is no specific diagnostic…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
Abstract Number: 2517 • ACR Convergence 2023
The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease
Erdem Bektas¹, Rabia Deniz², Zeliha Emrence³, Sema Sırma Ekmekci³, Neslihan Abacı³, Shirkhan Amikishiyev⁴, Yasemin Yalçınkaya⁴, Bahar Artim Esen⁴, Murat Inanç⁵ and Ahmet Gul⁶, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ²University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ³Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…
Abstract Number: 0801 • ACR Convergence 2023
LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Zhimian Wang, Xin Yu, Hua Chen and Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Dysregulated Th17 cells are implicated in Behçet's disease (BD). However, the underlying mechanism remains unclear. Here we aim to elucidate the mechanism of forkhead…
Abstract Number: 2519 • ACR Convergence 2023
A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease
Charles Jones¹, Zhanguo Li², Zhuoli Zhang³, Jian Wu⁴, Guixiu Shi⁵, Wenjie Zheng⁶, Jianping Tang⁷, Xiaobing Wang⁸, Lie Dai⁹, Lin Chen¹⁰, Yasong Li¹¹, Ling Wu¹², Yongfu Wang¹³, Shengyun Liu¹⁴, Yao Ke¹⁵, Jin Lin¹⁶, Zhenchun Zhang¹⁷, Jiankang Hu¹⁸, Wantai Dang¹⁹, Songlou Yin²⁰, Xin Tang²¹, Mingfei Zhu²², Jinfeng Lin²², Richard Jones²², Weiguo Wan²³ and xianjun Hu²², ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ³Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ⁴Suzhou University Affiliated First Hospital, Suzhou, China, ⁵the First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Shanghai Tongji Hospital, Shanghai, China, ⁸The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁹Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ¹⁰Jilin Provincial People's Hospital, Changchun, China, ¹¹11Zhejiang Provincial People's Hospital, Hangzhou, China, ¹²University of Hong Kong Shenzhen Hospital, Shenzhen, China, ¹³The First Affiliated Hospital of Baotou Medical College, Baotou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵Jiangsu Provincial People's Hospital, Nanjing, China, ¹⁶The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁷Linyi People's Hospital, Linyi, China, ¹⁸Pingxiang People’s Hospital, PingXiang, China, ¹⁹The First Affiliated Hospital of Chengdu Medical College, Chengdu, China, ²⁰Xuzhou Medical University Affiliated Hospital, Xuzhou, China, ²¹Bestudy (Shanghai) Medical Technology Co., Ltd, Shanghai, China, ²²Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²³Huashan Hospital Affiliated to Fudan University, Shanghai, China
Background/Purpose: Behçet's disease (BD) is a chronic and recurrent vascular inflammatory disease with major manifestations including oral ulcers, genital ulcers, skin damage and ophthalmitis, and…
Abstract Number: 1126 • ACR Convergence 2023
Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis
Ana Serrano-Combarro¹, Jose Luis Martin-Varillas², Raul Fernandez-Ramon³, Lara Sanchez-Bilbao⁴, Carmen Alvarez Reguera³, ELENA Aurrecoechea⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵HOSPITAL SIERRALLANA, Cantabria, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behcet's disease (BD) is a variable-vessel vasculitis with a high variability of clinical manifestations. The objective of our study was to identify clinical phenotypes…
Abstract Number: 127 • 2023 Pediatric Rheumatology Symposium
What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency
Patricia Pontes Aires¹, DANIELA GERENT PETRY PIOTTO¹, Andre Cunha¹, Sandro Perazzio² and Maria Teresa Terreri³, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade de So Paulo; Fleury Laboratories, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor alpha (TNF-alpha) induced protein 3 gene, or TNFAIP3, encodes the A20 protein, an important regulator of the NF-κB pathway. Since its…
Abstract Number: 1563 • ACR Convergence 2022
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Incomplete Behçet’s Disease
Fatma Alibaz-Oner¹, seda kutluğ ağaçkıran², Rabia Ergelen³, Fatma Temiz³, efe Soydemir³, Tulin Ergun⁴ and Haner Direskeneli⁵, ¹Marmara University, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Departmant of Internal Medicine, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Diagnosing Behçet's Disease (BD) can be a clinical challenge in patients presenting with limited organ manifestations, especially with single major organ involvement. We reported…
Abstract Number: 1564 • ACR Convergence 2022
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
Nuria Barroso-García¹, Belén Atienza-Mateo², Ivan Ferraz Amaro³, Diana Prieto-Peña², Ana De Vicente-Delmás⁴, Ricardo Blanco⁵ and Miguel Ángel González-Gay⁶, ¹Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital General Santa María del Puerto, Cádiz, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…
Abstract Number: 1565 • ACR Convergence 2022
Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease
Yesim Ozguler¹, Ziyan Lin², Ann Cavers³, gulen Hatemi⁴, Olivier Manches⁵ and Johannes Nowatzky³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ²NYU Grossman School of Medicine, NYU Langone Applied Informatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Recherche et Développement, Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France
Background/Purpose: Cellular immunity of Behçet's Disease (BD) remains poorly understood. Previous work has provided clues pointing to most innate and adaptive immune cell types in…
Abstract Number: 1566 • ACR Convergence 2022
Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
gulen Hatemi¹, Nur Beyza Tukek², Sinem Nihal Esatoglu¹, Yesim Ozguler³, Sitki Safa Taflan², Melike Melikoglu¹, Serdal Ugurlu⁴, Izzet Fresko¹, Zekayi Kutlubay⁵, Sebahattin Yurdakul¹, Hasan Yazici⁶ and Vedat Hamuryudan⁷, ¹Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpaşa, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, ⁶Letter to Editor Rheumatology, Istanbul, Turkey, ⁷Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). We aimed to survey the efficacy and safety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].